Leiden, The Netherlands, March 26, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that it has entered into an agreement with Hyupjin Corporation, a Seoul based Korean specialty pharma company, to commercialise RUCONEST® (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea.
Under the agreement, Hyupjin will drive the regulatory approval in Korea and purchase its commercial supplies of RUCONEST from Pharming at a fixed transfer price.
“The collaboration with a well-established company such as Hyupjin Corporation, as part of our ongoing efforts to extend the commercialisation of RUCONEST is very exciting for us" said Sijmen de Vries, CEO of Pharming. "We are very much looking forward to having RUCONEST distributed by such an experienced partner in Korea. With this agreement with Hyupjin Corporation, we now have two strong partners in Asia for the distribution of RUCONEST, whilst discussions continue with potential partners for other territories.”
Mr. Macsan Cho, General Manager of Hyupjin Corporation, said: “In our continuous effort to bring the most innovative therapeutics to patients, this agreement to distribute RUCONEST will now enable us to provide the Korean HAE patients access to this most innovative way to treat their disease. Given our long established relationships in immunology, we feel that RUCONEST complements our existing product portfolio very well and we look forward to getting started.”